Advertisement

Agents and Actions

, Volume 11, Issue 6–7, pp 624–627 | Cite as

Receptors for bradykinin in murine peritoneal macrophages: Modulation of short-term spreading

  • K. -W. Stahl
  • M. Roch-Arveiller
  • D. Regoli
  • J. P. Giroud
Proceedings of the 3rd European Workshop on Inflammation, Paris, 2–3 March 1981 Inflammation Revisited: Cellular Aspects

Abstract

The order of potency of bradykinin (bk) and four analogues, with respect to their modulation of peritoneal macrophage short-term spreading, suggests the presence of two peptide receptors in these cells which are responsible for antagonistic effects. Spreading inhibition and stimulation are mediated by the B1- and B2-types respectively. The implications of these results are highlighted in view of the hypothesis that the anti-inflammatory compound of the 1500−1000 molecular weight peptide fraction purified from malignant cell culture supernatants could be a kinin metabolite and a feedback mediator of inflammatory reactions.

Keywords

Peptide Molecular Weight Cell Culture Culture Supernatant Malignant Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Resume

L'effet exercé par la bradykinine (BK) et quatre analogues (kallidine (Lys-BK), Met-Lys-BK,1–8octa-BK, tyr8 (Me)-BK) sur l'étalement des macrophages péritonéaux de souris, suggère la présence de deux types de récepteurs sur la membrane de ces cellules. La stimulation des récepteurs de type B1 empêcheriat l'étalement des macrophages tandis que celle des récepteurs de type B2 favoriserait le phénomène. Les résultats obtenus confirmeraient l'hypothèse selon laquelle la fraction peptidique anti-inflammatoire (ak) purifiée à partir du surnageant de cellules tumorales malignes en culture serait un métabolite des kinines

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    R.M. Fauve andM.B. Hevin,Inflammation et résistance antitumorale: II Effets antagonistes de la bradykinine et d'une fraction isolée d'un surnageant de culture de cellules malignes sur l'étalement de macrophages, Ann. Immunol. (Inst. Pasteur)128C, 77–85 (1977).Google Scholar
  2. [2]
    K.-W. Stahl, M.B. Hevin andR. M. Fauve, Purification and gel filtration chromatography of an anti-inflammatory and phagotoxic peptide from murine malignant cells. InProc. Meeting on ‘Macrophage and Cancer’, pp. 271–280 (Eds.K. James, W.H. McBride andA. Stuart). University of Edinburgh Medical School, Edinburgh 1977.Google Scholar
  3. [3]
    K.-W. Stahl, D. Lambert, C. Rosenfeld andG. Mathe,Characterization of a phagotoxic tumour peptide from rat', Eur. J. Rheumatol. Inflamm.1, 330–335 (1978).Google Scholar
  4. [4]
    D. Regoli, F. Marceau andJ. Barabe,De novo formation of vascular receptors for bradykinin, Can. J. Physiol. Pharmac.56, 674–677 (1978).Google Scholar
  5. [5]
    M.A. Ondetti, B. Rubin andD.W. Cushman,Design of specific inhibitors of angiotensin-converting enzyme: a new class of orally active antihypertensive agents, Science196, 441–443 (1977).PubMedGoogle Scholar
  6. [6]
    K.-W. Stahl, I. Vergnon andG. Mathe,A semiquantitative test for assessing the phagotoxic effect of malignant cells, Fresenius Z. Anal. Chem.301, 196 (1980).CrossRefGoogle Scholar
  7. [7]
    M. Rabinovitch andM.J. de Stefano,Macrophage spreading in vitro: I. Inducers of spreading, Exp. Cell Res.,77, 323–324 (1973).CrossRefPubMedGoogle Scholar
  8. [8]
    D.B. Duncan,Multiple range and multiple F tests, Biometrics11, 1–42 (1955).Google Scholar
  9. [9]
    W.K. Park, S.A. St.Pierre, J. Barabe andD. Regoli,Synthesis of peptides by the solid-phase method. III bradykinin: fragments and analogs, Can. J. Biochem.56, 92–100 (1978).PubMedGoogle Scholar
  10. [10]
    P.A. Ward, R. Data andG. Till Regulatory control of complement-derived chemotactic and anaphylatoxin mediators. InProgress in Immunology vol. II, pp. 209–215 (Eds.L. Brunt andJ. Holborow) North Holland Publishing Co., Oxford 1974.Google Scholar
  11. [11]
    P. Di Mattei,Occurrence of bradykinin in human pulmonary carcinoma, Biochem. Pharmac.16, 909–911 (1966).CrossRefGoogle Scholar
  12. [12]
    R.M. Fauve andM.B. Hevin, Toxic effects of tumour cells on macrophages. InProc. Meeting on ‘Macrophage and Cancer’, pp. 264–270 (Eds.K. James, W.H. McBride andA. Stuart). University of Edinburgh Medical School, Edinburgh 1977.Google Scholar
  13. [13]
    K.-W. Stahl andI. Vergnon,Biosynthesis of antikinin in malignant tumours (Abs.) 13th FEBS Meeting, Jerusalem, Israël (1980).Google Scholar

Copyright information

© Birkhäuser Verlag 1981

Authors and Affiliations

  • K. -W. Stahl
    • 1
  • M. Roch-Arveiller
    • 2
  • D. Regoli
    • 3
  • J. P. Giroud
    • 2
  1. 1.Hôpital Paul Brousse: I.C.I.G. (I.N.S.E.R.M. U-50)VillejuifFrance
  2. 2.Hôpital Cochin: Département de PharmacologieParisFrance
  3. 3.Département de Physiologie et de Pharmacologie, Ecole de MédecineUniversité de SherbrookeSherbrookeCanada

Personalised recommendations